1 Low muscle strength is associated with cardiovascular autonomic neuropathy in patients with type 2 diabetes

2

- 3 Short Title: Muscle strength and cardiac autonomic neuropathy in T2DM
- 4 Chan-Hee Jung<sup>a</sup>, Yoon Young Cho<sup>a</sup>, Dug-Hyun Choi<sup>a</sup>, Bo-Yeon Kim<sup>a</sup>, Sang-Hee Jung<sup>b</sup>, Chul-Hee Kim<sup>a</sup>, Ji-Oh
- 5 Mok<sup>a</sup>\*
- 6 <sup>a</sup> Division of Endocrinology and Metabolism, Department of Internal Medicine, Soonchunhyang University
- 7 College of Medicine, Bucheon, South Korea
- 8 <sup>b</sup> Department of Obstetrics and Gynecology, CHA Bundang Medical Center, CHA University, Seongnam, South
- 9 Korea
- 10 \* Corresponding author:
- 11 Ji-Oh Mok,
- 12 Division of Endocrinology and Metabolism, Department of Internal Medicine,
- 13 Soonchunhyang University College of Medicine,
- 14 #170 Jomaru-ro, Wonmi-gu, Bucheon-si, Gyeonggi-do, 420-767, South Korea
- 15 Tel: 82-32-621-5156
- 16 Fax: 82-32-621-5016
- 17 E-mail: <u>hanna@schmc.ac.kr</u>
- 18 ORCID: Ji-Oh Mok <u>http://orcid</u>.org/0000-0003-4882-1206
- 19 Chan-Hee Jung <u>http://orcid.org/0000-0001-8988-0187</u>
- 20 Word count: 6591
- 21 Number of figures and tables: 1 figure, 3 tables

22 23 24 25 26 27 28 29

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

#### 31 Abstract

**Background:** Several studies have investigated whether sarcopenia is associated with diabetic microvascular complications, but very few have examined associations between sarcopenia and cardiovascular autonomic neuropathy (CAN) in patients with type 2 diabetes mellitus (T2DM). Therefore, we investigated associations of muscle strength (handgrip strength [HGS]) and mass (appendicular skeletal muscle mass index [ASMI]) and CAN in patients with T2DM.

37

Methods: We enrolled 342 T2DM patients (mean age 56.1±11.5 years; 58.2% male) in this retrospective, crosssectional study. Cardiovascular reflex tests were used to assess CAN according to Ewing's protocol. Relative HGS was determined after normalizing absolute HGS to body weight (HGS/body weight [kg]). We defined low HGS and low ASMI according to a consensus report of the Asian Group for Sarcopenia. Logistic regression analyses were carried out to assess the associations between relative HGS or ASMI quartiles and the presence of CAN in patients with T2DM.

44

45 **Results:** The prevalence rates of CAN, low HGS, and low ASMI in the study subjects were 34.8%, 17.3%, and 46 18.7%, respectively. Low HGS was significantly more prevalent in patients with CAN than those without CAN 47 (23.5% vs. 13.9%, p=0.025). The CAN scores were significantly and negatively correlated with relative HGS 48 but not with ASMI. Relative HGS was negative correlated with age, glycated hemoglobin, fasting plasma 49 glucose, hsCRP, body mass index, and HOMA-IR and positively correlated with ASMI. The prevalence of CAN 50 gradually increased with decreasing quartile of relative HGS (28.4% in Q4, 31.8% in Q3, 34.2% in Q2, and 45.3% 51 in O1, p=0.02 for trend). Multivariable-adjusted prevalence ratios (PRs) for CAN, determined by comparing the 52 first, second, and third quartiles with the fourth quartile of relative HGS, were 4.4 with a 95% confidence 53 interval (95% CI) of [1.1 to 17.3]), 2.3 (95% CI [0.8 to 6.9]), and 1.2 (95% CI [0.4 to 3.7]), respectively. The 54 prevalence of CAN and the PRs (95% [CI]) for CAN based on ASMI were not statistically significant.

55

56 Conclusions: Our findings suggest that low muscle strength rather than low muscle mass was significantly 57 associated with the presence of CAN. Therefore, HGS testing could help identify patients who would benefit 58 from screening for earlier diagnosis of CAN.

59

60 Keywords: appendicular skeletal muscle mass; cardiovascular autonomic neuropathy; handgrip strength; muscle

61 mass; muscle strength; type 2 diabetes

62	
63 64	
65	
66	
67	
68 60	
70	
71	
72	
73	
74	
75	
76 77	
78	
79	
80	
81	
82 02	
05 84	
85	
86	
87	
88	
89 90	
91	
92	
93	
94	
95	
90 97	
98	
99	
100	
101	
102	
104	
105	
106	
107	
108	
1109	

#### 113 Introduction

114

Cardiovascular autonomic neuropathy (CAN) refers to impaired autonomic control of the heart and vessels and 115 is a common microvascular complication of diabetes.<sup>1,2</sup> Numerous studies have reported that CAN is associated 116 117 with life-threatening clinical entities, such as silent myocardial ischemia, coronary artery disease, peri-operative 118 cardiovascular (CV) instability, and cardiac arrhythmia, resulting in increased cardiovascular and all-cause mortality.<sup>3-7</sup> Although there is definitive evidence of the prognostic relevance of CAN, it is underdiagnosed and 119 one of the most overlooked complications of diabetes.<sup>1,2</sup> Timely diagnosis and efforts to overcome under-120 121 diagnosis of CAN are important to avoid serious events. One strategy to overcome under-diagnosis of CAN is to 122 select candidates for active screening based on well known risk factors for the development and progression of 123 CAN in patients with T2DM, such as hyperglycemia, hypertension (HTN), dyslipidemia, and obesity; additional risk factors need to be identified to effectively predict CAN.<sup>8-12</sup> 124

125

Sarcopenia is defined as the loss of skeletal muscle mass and reduced muscle strength and/or physical performance.<sup>13</sup> In patients with T2DM, the presence of sarcopenia is receiving growing attention due to its increasing prevalence and the strong negative impact on prognosis.<sup>14</sup> Previous studies revealed a bidirectional relationship between sarcopenia and diabetic vascular complications.<sup>14-16</sup> Several studies have reported associations between sarcopenia and other diabetic microvascular complications<sup>17,18</sup> but, to our knowledge, there have been very few studies investigating the association between sarcopenia and CAN in T2DM.<sup>19,20</sup>

132

133 Previous studies have reported subjects with sarcopenia had a greater impairment of cardiac autonomic function and heart rate variability (HRV) than those without sarcopenia.<sup>21,22</sup> However, most such studies were carried out 134 in obese patients, operated patients, or elderly individuals without DM.<sup>21,22</sup> Because there have been very few 135 136 studies evaluating the impact of sarcopenia on CAN in subjects with T2DM, our goal in this study was to 137 investigate the relationships between CAN and two markers of sarcopenia (muscle strength and mass) in Korean 138 patients with T2DM. Association between sarcopenia and CAN could help identify patients who would benefit 139 from active screening for early diagnosis of CAN. Furthermore, interventions to modify sarcopenia may 140 improve the prognosis of patients with CAN.

- 141
- 142
- 143

#### 144 Methods

#### 145 Study subjects

We conducted a retrospective, cross-sectional study of patients with T2DM who were treated at Soonchunhyang University Bucheon Hospital between April 2020 and July 2023. Among patients who were treated at the Endocrinology and Metabolism Clinic, 342 who underwent handgrip strength measurement and bioelectrical impedance analysis (BIA) and were assessed for CAN were enrolled in this study. The study protocol was approved by the Institutional Review Board (IRB) of Soonchunhyang University School of Medicine, Bucheon Hospital (IRB number: 2024-04-001). The IRB waived the requirement for informed consent owing to the retrospective design of this medical record review study.

153

### 154 Assessment of muscle strength and muscle mass

155 Muscle strength was evaluated by HGS testing twice for each hand using a Smedley analog hand dynamometer 156 (No. 04125; MIS, Tokyo, Japan) in a standing position, and the maximum value was used in the analyses. Relative HGS was calculated as absolute HGS (kg) divided by body weight to reduce the impact of body size.<sup>23</sup> 157 158 We used bioimpedance analysis (BIA) to assess muscle mass. Appendicular skeletal muscle mass (ASM) was 159 calculated by summing the lean mass in the arms and legs, which primarily represents skeletal muscle mass. The 160 ASM index (ASMI) was calculated as ASM divided by height squared (ASM/Ht<sup>2</sup>; kg/m<sup>2</sup>). According to the consensus report of the Asian Working Group for Sarcopenia, we defined low muscle strength as HGS <26 kg 161 for men and <18 kg for women and defined low muscle mass as ASMI <7 kg/m<sup>2</sup> in men and <5.7 kg/m<sup>2</sup> in 162 163 women.<sup>13</sup> Subjects were divided into relative HGS quartiles or ASMI quartiles for statistical analysis.

164

#### 165 Diagnosis of CAN

166 Autonomic function tests (AFT) were performed by a single operator in the morning in a quiet room, and the 167 results were analyzed by one investigator. The subject was instructed to avoid consuming food, coffee, alcohol, 168 and smoking for at least 2 h before the tests. The presence of CAN was assessed using the five standard non-169 invasive cardiovascular reflex tests (CVRTs) proposed by Ewing and Clarke more than 30 years ago [24] and 170 that are now considered the cornerstone of diagnosis. The five CVRTs are the heart rate (HR) responses to (i) 171 deep breathing (beat-to-beat variation), (ii) standing (30:15 ratio), and (iii) the Valsalva maneuver and the blood 172 pressure (BP) response to (iv) standing and (v) a sustained handgrip. The CVRTs were assessed automatically 173 from electrocardiography recordings using the DICAN evaluation system (Medicore Co., Ltd., Seoul, Korea).

Each CVRT was assigned a score of 0, 0.5, or 1 depending on whether the result was normal, borderline, or abnormal, respectively as previously described by Bellavere et al.<sup>25</sup> The presence of CAN was quantified by summing the scores of the five tests, and was defined as the presence of at least two abnormal tests or an autonomic neuropathy score  $\geq 2$ .

178

#### 179 **Other covariates**

180 Height and weight were measured to the nearest 0.1 cm and 0.1 kg, respectively. Body mass index (BMI) was 181 calculated as body weight (kg) divided by height squared (meters). Blood samples were collected after overnight 182 fasting. Glycated hemoglobin (HbA1c) was measured by ion-exchange high-performance liquid 183 chromatography (Bio-Rad, Hercules, CA, USA) using a methodology aligned with the Diabetes Control and 184 Complications Trial and National Glycohemoglobin Standardization Program standards. Estimated glomerular 185 filtration rate (eGFR) was calculated using the Modification of Diet in Renal Disease study equation, and the 186 urine albumin-to-creatinine ratio (ACR) was assessed in spot urine specimens. Insulin resistance (IR) status was 187 evaluated using the formula for the homeostasis model assessment-insulin resistance (HOMA-IR) index: 188 (fasting insulin  $[\mu IU/mL] \times$  fasting plasma glucose [mmol/L])/22.5.

189

### 190 Statistical analysis

191 Data are reported as mean ± standard deviation (SD) or median (interquartile range) for continuous variables or 192 as number of subjects (percentage) for categorical variables. The baseline characteristics of the study subjects 193 according to the presence of CAN were compared using two-sample independent t tests for continuous variables 194 and Chi-square tests for categorical variables as appropriate. To evaluate linear trends in the prevalence of CAN 195 according to relative HGS and ASMI quartiles, p values were calculated using linear-by-linear association tests 196 for categorical variables. Correlations between relative HGS, ASMI, and CAN score were assessed using the 197 Spearman's rank correlation coefficient. Multivariate logistic regression analyses were performed to estimate 198 the independent effects of relative HGS or ASMI quartile on the prevalence ratios (PRs) of CAN after 199 adjustment for possible confounding factors (age, sex, BMI, current alcohol drinking, current smoking, duration 200 of diabetes, HTN, HbA1c, triglyceride (TG), low density lipoprotein-cholesterol (LDL-C), eGFR, ACR, high-201 sensitivity c-reactive protein (hsCRP), HOMA-IR, beta-blockers, angiotensin-receptor blockers (ARBs), 202 sodium-glucose cotransporter 2 inhibitors (SGLT2is), and insulin treatment). Skewed variables (hsCRP, TG, and 203 ACR) were transformed logarithmically to improve normality before analyses. P values less than 0.05 were

204	considered significant. All statistical analyses were performed using SPSS 19.0 statistical software (IBM Corp.,
205	Armonk, NY, USA).
206	
207	
208	
209	
210	
211	
212	
213	
214	
215	
216	
217	
218	
219	
220	
221	
222	
223	
224	
225	
226	
227	
228	
229	
230	
231	
232	
233	

#### 234 Results

#### 235 General characteristics of the subjects

The general characteristics of the study subjects are presented in Table 1. A total of 342 Korean T2DM patients (199 male, 143 female, mean age  $56.1\pm11.5$  years) was enrolled in this retrospective, cross-sectional study. The CAN prevalence was 34.8% (n=119), and the mean BMI and duration of DM were 25.7 kg/m<sup>2</sup> and 7.0 years, respectively. The mean HbA1c of the study population was 8.5%, and the proportions of subjects treated with oral hypoglycemic agents (OHA) or insulin were 65.2% and 15.8%, respectively. The mean HGS and ASMI were 29.7 kg and 7.3 kg/m<sup>2</sup>, respectively, and the proportion (number) of patients with low HGS and low ASMI were 17.3% (n=59) and 18.7% (n=64).

243

### 244 Comparisons of clinical characteristics according to the presence or absence of CAN

245 The general characteristics of subjects according to the presence or absence of CAN are presented in Table 1. 246 The mean HGS and relative HGS were lower in subjects with CAN than in subjects without CAN (27.6 kg vs. 247 30.8 kg, p=0.004, 0.40 vs. 0.44, p=0.006, respectively). A greater proportion of subjects with CAN had low 248 HGS than those without CAN (23.5% vs. 13.9%, p=0.025). There were no significant differences in mean age, 249 duration of DM, BMI, HTN, glucose parameters, lipid profiles, eGFR, ACR, hsCRP, and HOMA-IR according 250 to the presence or absence of CAN. In addition, there were no significant differences in treatment modalities 251 such as insulin or OHA between subjects with CAN and those without CAN. The proportion of subjects using 252 SGLT2is or beta-blockers was significantly larger in subjects without CAN than those with CAN (17.5% vs. 253 7.6%, p=0.004, 6.3% vs. 1.7, p=0.011, respectively), and use of ARB was more prevalent in those with CAN 254 than those without CAN (30.3 % vs. 27.4%, p=0.042).

255

### 256 Prevalence of CAN according to relative HGS and ASMI quartiles

The prevalence of CAN according to relative HGS and ASMI quartiles is shown in Figure 1. The prevalence declined significantly and progressively from the lowest to highest quartiles of relative HGS (45.3%, 34.2%, 31.8%, and 28.4%, respectively, p=0.02 for trend; Fig. 1[a]). On the other hand, the prevalence of CAN did not differ from the lowest to highest quartiles of ASMI (36.8%, 35.2%, 34.5%, and 33%, respectively, p=0.197 for trend; Fig. 1[b]).

262

### 263 Bivariate correlations of CAN score and relative HGS and ASMI with clinical variables

264 Correlations of CAN score, relative HGS, and ASMI with clinical variables are shown in Table 2. The CAN 265 score showed a significant negative correlation with relative HGS (r=-0.137, p=0.012). However, there was no 266 significant correlation between CAN score and ASMI. Relative HGS showed significant negative correlations 267 with age, FBS, HbA1c, hsCRP, BMI, and HOMA-IR (r=-0.116, p=0.032; r=-0.132, p=0.015; r=-0.119, p=0.03; 268 r=-0.201, p=0.003; r=-0.387, p<0.001; and r=-0.198, p=0.001, respectively) and a positive correlation with 269 ASMI (r=0.334, p<0.001). The ASMI was negatively correlated with age and HDL-C (r=-0.403, p<0.001; r=-270 0.172, p=0.002, respectively) and positively correlated with TG, eGFR, BMI, and HOMA-IR (r=0.192, p<0.001; 271 r=0.158, p=0.003; r=0.439, p<0.001; and r=0.12, p=0.049, respectively).

272

### 273 Associations between CAN and relative HGS or ASMI quartile

Multivariate logistic regression analysis adjusted for confounding variables was used to evaluate the associations between HGS, ASMI, and CAN (Table 3). When the highest relative HGS quartile group was used as a reference in the univariate model, patients in the lowest quartile (Q1) were 2.1-fold more likely to have CAN (OR 2.1; 95% CI [1.1 to 3.9]). This significant association for group Q1 remained even after adjusting for age, duration of DM, HTN, smoking, alcohol, BMI, HbA1c, eGFR, ACR, TC, hsCRP, HOMA-IR, insulin treatment, SGLT2is, beta-blockers, and ARBs (OR 4.4, 95% CI [1.1 to 17.3]). However, there were no significant association between ASMI and CAN in either the unadjusted model or after multivariate adjustment.

- 281
- 282
- 283
- 284
- 285
- 286
- 287

#### 289 Discussion

We demonstrated that T2DM patients with low HGS are at a higher risk for the presence of CAN; however, low ASMI was not associated with the presence of CAN. These findings suggest that assessment of muscle strength using HGS could be invaluable in clinical practice to identify high-risk T2DM subjects who require earlier and active screening for CAN.

294

295 There is considerable variation in the reported prevalence of CAN, depending upon the diagnostic criteria, test tool, interpretation of results, and study population.<sup>2</sup> The prevalence of clinical and subclinical CAN has been 296 297 estimated to be 20–65% of diabetic patients, which is greater than the prevalence of other diabetic complications. 298 <sup>2,26</sup> There is definitive evidence of the prognostic relevance of CAN for all-cause and CV mortality, and the risks are increased even at an asymptomatic stage.<sup>27</sup> Despite the importance of early detection of CAN, there are 299 300 several possible barriers to testing: there is no harmonized definition of CAN, there is a wide variety of tools for 301 assessing CAN, testing can be time-consuming and cumbersome, the results may be difficult to interpret, specific treatments for CAN are lacking, and testing may be considered unnecessary in asymptomatic cases.<sup>28</sup> 302 303 Despite these barriers to testing, screening for CAN using Ewing's tests and HRV may allow diagnosis of at an 304 earlier stage where risk factor modification is possible and reversibility is more likely. The established risk 305 factors for development and progression of CAN are age, duration of diabetes, glycemic control, JTN, dyslipidemia, obesity, and smoking.<sup>9,11,29</sup> In addition, some studies have suggested glycemic variability, vitamin 306 D, oxidative stress, and chronic inflammation as additional risk factors for CAN.<sup>30-32</sup> 307

308

309 There are a few reports in the literature correlating sarcopenia with cardiac autonomic modulation. Early studies 310 suggested that low muscle mass and muscle strength lead to reduced parasympathetic modulation and may be 311 associated with abnormal autonomic modulation. A cross-sectional study of 76 elderly Brazilians showed that greater impairment of HRV was evident in subjects with sarcopenia than in those without sarcopenia.<sup>22</sup> In the 312 313 study, muscular strength was assessed using HGS, muscle mass was assessed using the skeletal muscle index, 314 and cardiac autonomic modulation was evaluated using a heart rate (HR) monitor to record five minutes of 315 successive RR intervals. The analysis of the RR-interval variability was carried out in time and frequency 316 domains. The non-sarcopenia group was that with adequate muscle strength and physical performance but 317 insufficient muscle mass or adequate muscle mass. Sarcopenia was defined as insufficient muscle mass plus

insufficient muscle strength and/or poor physical performance. The parameters of autonomic heart rate modulation differed significantly between elderly sarcopenic and non-sarcopenic participants. Elderly sarcopenic participants exhibited lower parasympathetic-associated modulation. Baek et al. investigated the relationship between overweight with low muscle mass and cardiac autonomic function as assessed by HRV in a five-min ECG recording in 1,150 healthy Korean workers.<sup>21</sup> The overweight group showed reduced parasympathetic modulation compared with the non-overweight group. In addition, the overweight-with-lowmuscle-mass group had a lower HRV than the overweight-with-high-muscle-mass group.

325 Hyperinsulinemia and IR can induce the development of a sympathovagal imbalance with SNS predominance<sup>33</sup>; 326 hyperinsulinemia-induced SNS activation may then result in further IR and hyperinsulinemia. Weight loss using 327 lifestyle interventions and bariatric surgery may help improve cardiac autonomic function by reducing IR and 328 hyperinsulinemia, leading to a reduction in SNS activation. Several studies have reported that weight reduction through bariatric surgery (BS) improves cardiac autonomic modulation.<sup>34,35</sup> Furthermore, the presence of low 329 330 muscle mass and/or strength in the preoperative period has been shown to attenuate the improvement in cardiac autonomic function after BS compared with patients without sarcopenia.<sup>36</sup> A recent study by Carvalho et al. 331 332 showed that women who underwent BS experienced less of an improvement of HRV during the follow-up 333 period among women with low muscle mass and /or handgrip strength.<sup>36</sup>

334

335 To the best of our knowledge, there have been few studies assessing associations of sarcopenia and CAN in T2DM, and the findings were not consistent with those of our study.<sup>19,20</sup> The primary aim of the study by Mikura 336 337 et al. was to investigate the association between sarcopenia and severity of diabetic peripheral neuropathy (DPN) 338 in 261 Japanese patients (median age; 67 years, median duration of DM; 10 years).<sup>19</sup> They also evaluated the 339 association of autonomic neuropathy and sarcopenia. The coefficient of variation of the R-R interval was 340 assessed using ECG as a marker of autonomic function, and autonomic neuropathy was noted if CV R-R was 341 lower than the reference ranges. In addition, sarcopenia was identified based on the AWGS 2019 diagnostic 342 criteria, consistent with our current study. The Mikura et al. study showed that neither autonomic neuropathy nor 343 DPN was significantly correlated with sarcopenia. Another study by Ozgur Y et al. examined the relationships 344 between several diabetic neuropathy subtypes and low muscle mass/low muscle strength in a cross-sectional study of 602 diabetic patients (mean age; 60.2 years).<sup>20</sup> In the study, diabetic neuropathy was classified into 345 346 subtypes of diabetic sensorimotor polyneuropathy or diabetic autonomic neuropathies (DAN), and DAN was 347 further subclassified into four subgroups of gastrointestinal autonomic neuropathy, genitourinary autonomic

348 neuropathy, sudomotor autonomic neuropathy, and CAN. The Ozgur study used HR while sitting, HR response 349 to standing, and BP response to standing to diagnose CAN in the presence of abnormality in two of three tests. 350 When the DAN sub-groups were considered, the prevalence of CAN did not differ significantly between the 351 sarcopenic and non-sarcopenic groups. In addition, there was no significant association between CAN and low 352 muscle mass or low muscle strength in logistic regression analyses. Specifically, the prevalence of diabetic 353 neuropathy in the low muscle strength group was greater than in the low muscle mass group. They found that 354 although the skeletal muscle mass index was higher in low muscle strength when compared to low muscle mass 355 group, their muscle qualities were much lower in low muscle strength. The latter finding suggests that loss of 356 muscle strength is more important than loss of muscle mass in terms of the prognosis of diabetic neuropathy.

In our study, subjects with low HGS had a greater CAN prevalence than subjects with low ASMI (47.5% vs. 31.2%, data not shown). The prevalence of CAN increased progressively with decreasing quartile of relative HGS, and the lowest quartile of relative HGS was significantly associated with the PR of CAN. However, the prevalence of CAN and PRs for CAN based on ASMI were not significant. Our findings study also suggest that muscle strength may be a more useful diagnostic marker of the presence of CAN than muscle mass.

362

363 Most previous studies used HRV derived from ECG recordings as a diagnostic tool for assessment of CAN, 364 whereas there have been no studies investigating the correlation of CAN score based on CVRTs as assessed by Ewing's test and sarcopenia parameters. Although agreement between indices of HRV derived from ECGs and 365 CVRTs has been reported, CVRTs are the gold standard for the diagnosis of CAN.<sup>37</sup> We analyzed the 366 367 correlations of relative HGS, ASMI, and CAN score with clinical parameters and found that relative HGS was 368 significantly and negatively correlated with hsCRP, BMI, HOMA-IR, and glucose parameters. The significant 369 correlations of relative HGS with inflammatory markers, obesity, IR index, and glycemia, all of which are risk 370 factors of CAN, indicate that they contribute to the association between muscle strength and presence of CAN. 371 On the other hand, ASMI was marginally and positively correlated with HOMA-IR, but there was no correlation 372 with hsCRP and glucose parameters. Overall, the CAN score was significantly correlated only with relative 373 HGS not with ASMI. In a Danish multicenter cross-sectional study of T2DM patients, CAN was independently associated with high BP, BMI, and smoking.<sup>26</sup> However, in our study, the CAN score was not significantly 374 375 correlated with duration of diabetes, HbA1c, lipid profile, hsCRP, eGFR, ACR, BMI, or HOMA-IR. Previous 376 studies also reported that age, duration of diabetes, eGFR, BP, lipid profile, and HbA1c did not differ between subjects with and without CAN.<sup>30</sup> 377

378

379 Among sarcopenia parameters, muscle strength may represent muscle quality or function. Several studies have 380 reported that low muscle strength, but not muscle mass, is associated with poor physical function and higher mortality.<sup>23,38</sup>, and that muscle strength more strongly influences various diabetic complications than does 381 muscle mass in patients with T2DM.<sup>17</sup> These findings suggest that measuring muscle mass alone may not be 382 383 sufficient to predict and protect against DM complications, and preservation of muscle strength may be more 384 important. A previous joint international longitudinal study suggested that HGS is a useful predictor of the risk of CVD and mortality.<sup>23</sup> In addition, a subanalysis of the ORIGIN trial showed HGS to be associated with CVD 385 mortality in patients with T2DM.<sup>38</sup> 386

387

388 The mechanisms underlying the association between sarcopenia and cardiac autonomic dysfunction are unclear, 389 but some explanations can be suggested. First, CAN and sarcopenia have multifactorial etiologies and common 390 risk factors. Hyperinsulinemia or IR results in early CAN through the development of a sympathovagal imbalance with SNS activation.<sup>33,39</sup>, while IR has also been suggested as a main underlying mechanism of 391 392 sarcopenia. In addition, increased low-grade chronic inflammation is a common feature in patients with sarcopenia and has been associated with decline in muscle mass and strength and reduced HRV.<sup>40</sup> Second, 393 394 increased reactive oxygen species and mitochondrial dysfunction can lead to muscle wasting and autonomic dysfunction.<sup>41,42</sup> Third, the myokine irisin produced by skeletal muscle may serve as an important cross-organ 395 396 messenger linking skeletal muscle with the brain, adipose tissue, and CV system to integrate energy expenditure with CV activity.<sup>43</sup> Irisin controls HR, modulates vagal tone, and promotes CV protection.<sup>44</sup> Previous studies 397 showed a positive correlation between irisin and HGS in a multivariate analysis.<sup>45,46</sup> Irisin has been reported to 398 399 be strongly associated with muscle strength and was recently suggested to be a candidate factor to explain the 400 relationship between muscle strength and parasympathetic tone to the heart, promoting a cardioprotective role.<sup>43,44</sup> However, since serum irisin was not measured in our study, a direct causal relationship among irisin, 401 402 muscle strength, and autonomic modulation in patients with T2DM needs to be further examined.

403

While there is no conclusive evidence of a successful disease-modifying therapy, multifactorial interventions including glycemic control and weight loss might be effective. In addition, beta blockers and renin-angiotensinaldosterone system inhibitors are known to have a positive effect on autonomic dysfunction, and emerging data on SGLT2i suggest a modulatory effect on cardiovascular autonomic function.<sup>47,48</sup> In our current study,

408 adjustment of the models for these medications did not substantially change the results.

410	One strength of the present study is that, to the best of our knowledge, it is the first to investigate directly the
411	relationship between HGS and CAN using CVRTs in patients with T2DM. This study also has some limitations.
412	First, we excluded patients with no CVRT, BIA, or HGS results, which led to a small sample size and a potential
413	for selection bias. Second, because of the retrospective, cross-sectional nature of this study, we could not
414	determine causality of the relationship between CAN and sarcopenia. Future prospective or interventional
415	studies are needed to investigate the longitudinal associations among HGS, ASMI, and CAN in a large sample
416	size.
417	
418	In conclusion, we demonstrated that HGS was associated with the presence of CAN in Korean patients with
419	T2DM. We also found that ASMI was not associated with the presence of CAN. Low muscle strength is an
420	important cause of morbidity in T2DM and CAN is also a serious complication. In patients with both low
421	muscle strength and CAN, poor quality of life may be expected. Therefore, low muscle strength may be
422	recognized with a simple HGS test performed in clinical practice, allowing early diagnosis of CAN.
423	
424	
425	
426	
427	
428	
429	
430	
431	
422	
432	
433	
434	
435	
436	

4	3	7
	-	

### 438 Author contributions

- 439 CHJ and JOM contributed to the conception and design of the study; CHJ, YYC, DHC, BYK, and CHK
- 440 contributed to data collection and management; CHJ, YYC, DHC, BYK, SHJ, CHK, and JOM contributed to
- 441 acquisition, analysis, or interpretation of the data; CHJ and SHJ contributed to writing the manuscript; JOM
- 442 contributed to manuscript revision. All authors read and approved the final manuscript.
- 443

## 444 Acknowledgements

- 445 This study was supported by a grant from Soonchunhyang University.
- 446
- 447 ORCID
- 448 Chan-Hee Jung <u>https://orcid.org/0000-0001-8988-0187</u>
- 449 Ji-Oh Mok <u>https://orcid.org/0000-0003-4882-1206</u>
- 450
- 451 Disclosures
- 452 None.
- 453 **Conflicts of interest**
- 454 The authors have no conflicts of interest to declare.
- 455
- 456 Ethical statement

457 The study was approved by the Institutional Review Board of Soonchunhyang University Bucheon Hospital.

- 458
- 459 Informed consent
- 460 Not applicable
- 461
- 462
- 463
- 464
- 465

466

#### 467 **References**

- 468 1. Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. *Circulation*. 2007;115:387-397
- 2. Spallone V, Ziegler D, Freeman R, Bernardi L, Frontoni S, Pop-Busui R, Stevens M, Kempler P, Hilsted J,
- 470 Tesfaye S, Low P, Valensi P; Toronto Consensus Panel on Diabetic Neuropathy. Cardiovascular autonomic
- 471 neuropathy in diabetes: clinical impact, assessment, diagnosis, and management. Diabetes Metab Res Rev.
- 472 2011;27:639-653
- 473 3. Ewing DJ, Boland O, Neilson JM, Cho CG, Clarke BF. Autonomic neuropathy, QT interval lengthening, and
  474 unexpected deaths in male diabetic patients. *Diabetologia*. 1991;34:182-185
- 475 4. Gerritsen J, Dekker JM, TenVoorde BJ, Kostense PJ, Heine RJ, Bouter LM, Heethaar RM, Stehouwer CD.
- 476 Impaired autonomic function is associated with increased mortality, especially in subjects with diabetes,
- 477 hypertension, or a history of cardiovascular disease: the Hoorn Study. *Diabetes Care*. 2001;24:1793-1798
- 5. Meyer C, Milat F, McGrath BP, Cameron J, Kotsopoulos D, Teede HJ. Vascular dysfunction and autonomic
  neuropathy in Type 2 diabetes. *Diabet Med*. 2004;21:746-751
- 480 6. Maser RE, Lenhard MJ. Cardiovascular autonomic neuropathy due to diabetes mellitus: clinical
- 481 manifestations, consequences, and treatment. J Clin Endocrinol Metab. 2005;90:5896-5903
- 482 7. Pop-Busui R, Evans GW, Gerstein HC, Fonseca V, Fleg JL, Hoogwerf BJ, Genuth S, Grimm RH, Corson MA,
- 483 Prineas R; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of cardiac autonomic
- 484 dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
- 485 Diabetes Care. 2010;33:1578-1584
- 486 8. Valensi P, Paries J, Attali JR. Cardiac autonomic neuropathy in diabetic patients: influence of diabetes
  487 duration, obesity, and microangiopathic complications—the French multicenter study. *Metabolism*.
  488 2003;52:815-820
- 489 9. Ang L, Jaiswal M, Martin C, Pop-Busui R. Glucose control and diabetic neuropathy: lessons from recent
  490 large clinical trials. *Curr Diab Rep.* 2014;14:528
- 491 10. Guarino D, Nannipieri M, Iervasi G, Taddei S, Bruno RM. The role of the autonomic nervous system in the
  492 pathophysiology of obesity. *Front Physiol*. 2017;8:665
- 493 11. Andersen ST, Witte DR, Fleischer J, Andersen H, Lauritzen T, Jorgensen ME, Jensen TS, Pop-Busui R,
- 494 Charles M. Risk factors for the presence and progression of cardiovascular autonomic neuropathy in type 2
- diabetes: ADDITION-Denmark. Diabetes Care. 2018;41:2586-2594

- 496 12. Williams SM, Eleftheriadou A, Alam U, Cuthbertson DJ, Wilding JPH. Cardiac Autonomic Neuropathy in
- 497 Obesity, the Metabolic Syndrome and Prediabetes: A Narrative Review. *Diabetes Ther*. 2019;10:1995-2021
- 498 13. Chen LK, Woo J, Assantachai P, Auyeung TW, Chou MY, Iijima K, Jang HC, Kang L, Kim M, Kim S, et al.
- 499 Asian working group for sarcopenia 2019 consensus update on sarcopenia diagnosis and treatment. J Am Med
- 500 *Dir Assoc*. 2020;21:300-307
- 501 14. Morley JE, Malmstrom TK, Rodriguez-Manas L, Sinclair AJ. Frailty, sarcopenia and diabetes. J Am Med
- 502 Dir Assoc. 2014;15:853-859
- 503 15. Boonpor J, Pell JP, Ho FK, Celis -Morales C, Gray SR. In people with type 2 diabetes, sarcopenia is
- sold associated with the incidence of cardiovascular disease: a prospective cohort study from the UK biobank.
- 505 Diabetes Obes Metab. 2024;26:524-531
- 506 16. Xia LF, Li JB, Tian GS, Jiang WR, Li YS, Lin CY, Qiu HN, Wu F, Wang JJ, Li CJ, et al. Effect of sarcopenia
- 507 on 10-year risk of atherosclerotic cardiovascular disease in patients with type 2 diabetes mellitus. *Diabetes*
- 508 Metab Syndr Obes. 2024;17:1621-1634
- 509 17. Fukuda T, Bouchi R, Takeuchi T, Nakano Y, Murakami M, Minami I, Izumiyama H, Hashimoto K,
- 510 Yoshimoto T, Ogawa Y. Association of diabetic retinopathy with both sarcopenia and muscle quality in patients
- 511 with type 2 diabetes: a cross-sectional study. BMJ Open Diabetes Res Care. 2017;27:e000404
- 512 18. Wannarong T, Sukpornchairak P, Naweera W, Geiger CD, Ungprasert P. Association between diabetic
  513 peripheral neuropathy and sarcopenia: A systematic review and meta-analysis. *Geriatr Gerontol Int.*514 2022;22:785-789
- 515 19. Mikura K, Kodama E, Lida T, Imai H, Hashizume M, Kigawa Y, Tadokoro R, Sugisawa C, Endo K, Lizaka
- 516 T, et al. Association between sarcopenia and the severity of diabetic polyneuropathy assessed by nerve
- 517 conduction studies in Japanese patients with type 2 diabetes mellitus. J Diabetes Invest. 2022;13:1357-1365
- 518 20. Ozgur Y, Akin S, Keskin O. Relationship between diabetic neuropathy and sarcopenia. *Prim Care Diabetes*.
  519 2019:13:521-528
- 520 21. Baek J, Park D, Kim I, Won JU, Hwang J, Roh J. Autonomic dysfunction of overweight combined with low
  521 muscle mass. *Clin Auton Res.* 2013;23:325-331
- 522 22. Freitas VP, Passos RDS, Oliveira AA, Ribeiro IJS, Freire IV, Schettino L, Teles MF, Casotti CA, Pereira R.
- 523 Sarcopenia is associated to an impaired autonomic heart rate modulation in community-dwelling old adults.
- 524 Arch Gerontol Geriatr. 2018;76:120-124
- 525 23. Roberts HC, Denison HJ, Martin HJ, Patel HP, Syddall H, Cooper C, Sayer AA. A review of the

- 526 measurement of grip strength in clinical and epidemiological studies: towards a standardised approach. Age
- 527 Ageing. 2011;40:423-429
- 528 24. Ewing DJ, Martyn CN, Young RJ, Clarke BF. The value of cardiovascular autonomic function tests: 10 years
- 529 experience in diabetes. *Diabetes Care*. 1985;8:491-498
- 530 25. Bellavere F, Bosello G, Fedele D, Cardone C, Ferri M. Diagnosis and management of diabetic autonomic
- neuropathy. Br Med J (Clin Res Ed). 1983;287:61
- 532 26. Fleischer J, Yderstraede K, Gulichsen E, Jakobsen PE, LervangHH, Eldrup E, Nygaard H, Tarnow L,
- 533 Ejskjaer N. Cardiovascular autonomic neuropathy is associated with macrovascular risk factors in type 2
- 534 diabetes: new technology used for routine large-scale screening adds new insight. J Diabetes Sci Technol.
- 535 2014;8:874-880
- 536 27. Pop-Busui R, Boulton AJM, Feldman EL, et al. Diabetic neuropathy: a position statement by the American
- 537 Diabetes Association. *Diabetes Care*. 2017;40:136-154
- 538 28. Tesfaye S, Boulton AJM, Dyck PJ, Freeman R, Horowitz M, Kempler P, Lauria G, Malik RA, Spallone V,
- 539 Vinik A, et al. Diabetic neuropathies: Update on definitions, diagnostic criteria, estimation of severity, and
- 540 treatments. *Diabetes Care*. 2010;33:2285-2293
- 541 29. Voulgari C, Psallas M, Kokkinos A, Argiana V, Katsilambros N, Tentolouris N. The association between
- 542 cardiac autonomic neuropathy with metabolic and other factors in subjects with type 1 and type 2 diabetes. J
- 543 Diabetes Complications. 2011;25:159-167
- 544 30. Gad H, Elgassim E, Mohammed I, Alhaddad AY, Aly HAHZ, Cabibihan J, Al-Ali A, Sadasivuni KK,
- 545 Petropoulos I, Ponirakis G, et al. Cardiovascular autonomic neuropathy is associated with increased glycemic
- 546 variability driven by hyperglycemia rather than hypoglycemia in patients with diabetes. *Diabetes Res Clin Pract*.
- 547 2023;200:110670
- 548 31. Jung CH, Jung SH, Kim KJ, Kim BY, Kim CH, Kang SK, Mok JO. The relationship between vitamin D
  549 status and cardiac au-tonomic neuropathy in patients with type 2 diabetes mellitus. *Diab Vasc Dis Res.*550 2015;12:342-51
- 32. Herder C, Schamarek I, Nowotny B, Carstensen-Kirberg M, Straßburger K, Nowotny P, Kannenberg JM,
- 552 Strom A, Puttgen S, Mussig K, et al; German Diabetes Study Group. Inflammatory markers are associated with
- cardiac autonomic dysfunction in recent-onset type 2 diabetes. *Heart.* 2017;103:63-70
- 33. Saito I, Maruyama K, Eguchi E, Kato T, Kawamura R, Takata Y, Onuma H, Osawa H, Tanigawa T. Low
- 555 heart rate variability and sympathetic dominance modifies the association between insulin resistance and

- 556 metabolic syndrome—the Toon Health Study. Circ J. 2017;81:1447-1453
- 557 34. Kokkinos A, Alexiadou K, Liaskos C, Argyrakopoulou G, Balla I, Tentolouris N, Moyssakis I,
- 558 KatsilambrosN, Vafiadis I, Alexandrou A, et al. Improvement in cardiovascular indices after Roux-en-Y gastric
- bypass or sleeve gastrectomy for morbid obesity. *Obes Surg.* 2013;23:31-38
- 560 35. Benjamim CJR, Pontes YMM, de Sousa Junior FW, Porto AA, Bueno Junior CR, Marcelino da Silva AA,
- 561 Ferro Cavalcante TC, Garner DM, Valenti VE. Does bariatric surgery improve cardiac autonomic modulation
- assessed by heart rate variability? A systematic review. Surg Obes Relat Dis. 2021;17:1497-1509
- 563 36. Crispim Carvalho NN, Baccin Martins VJ, da Nóbrega VA, de Arruda Neta ADCP, Cavalcante da Fonseca
- 564 LA, Bandeira F, de Brito Alves JL. Effects of Preoperative Sarcopenia-Related Parameters on Cardiac
- Autonomic Function in Women with Obesity Following Bariatric Surgery: A One-Year Prospective Study.
   *Nutrients*. 2023;15:2656
- 567 37. Pop-Busui R, Backlund JC, Bebu I, Braffett BH, Lorenzi G, White NH, Lachin JM, Soliman EZ and
- 568 DCCT/EDIC Research Group. Utility of using electrocardiogram measures of heart rate variability as a measure 569 of cardiovascular autonomic neuropathy in type 1 diabetes patients. *J Diabetes Investig*. 2022;13:125-133
- 570 38. Lopez-Jaramillo P, Cohen DD, Gomez-Arbelaez D, Bosch J, Dyal L, Yusuf S, Gerstein HC; ORIGIN trial
- 571 investigators. Association of handgrip strength to cardiovascular mortality in pre-diabetic and diabetic patients:
- a subanalysis of the ORIGIN trial. *Int J Cardiol*. 2014;174:458-461.
- 573 39. Williams S, Eleftheriadou A, Alam U, Cuthbertson DJ, Wilding JPH. Cardiac autonomic neuropathy in
- obesity, the metabolic syndrome and prediabetes: A narrative review. *Diabetes Ther*. 2019;10:1995-2021
- 40. da Fonseca GWP, von Haehling S. Sarcopaenia complicating heart failure. *Eur Heart J Suppl.* 2019;21:L20–
  L23
- 41. Tse G, Yan BP, Chan YW, Tian XY, Huang Y. Reactive oxygen species, endoplasmic reticulum stress and
- 578 mitochondrial dysfunction: The link with cardiac arrhythmogenesis. *Front Physiol*. 2016;7:313
- 579 42. Abrigo J, Elorza A, Riedel CA, Vilos C, Simon F, Cabrera D, Estrada L, Cabello-Verrugio C. Role of
- 580 oxidative stress as key regulator of muscle wasting during cachexia. Oxid Med Cell Longev. 2018;2018:2063179
- 43. Zhang W, Chang L, Zhang C, Zhang R, Li Z, Chai B, Li J, Chen E, Mulholland M. Central and peripheral
- 582 irisin differentially regulate blood pressure. Cardiovasc Drugs Ther. 2015;29:121-127
- 583 44. Brailoiu E, Deliu E, Sporici RA, Brailoiu GC. Irisin evokes bradycardia by activating cardiac-projecting
- neurons of nucleus ambiguous. *Physiol Rep.* 2015;3:e12419
- 45. Munoz IYM, Romero ESC, Padilla TC, Benitez JGS, Romero MSC, Morales LPM, Bravo GGH, Garcia JJG.

- 586 Association of irisin serum concentration and muscle strength in normal-weight and overweight young women.
- 587 Front Endocrinol. 2019;10:621
- 46. Planella-Farrugia C, Comas F, Sabater-Masdeu M, Moreno M, Moreno-Navarrete JM, Rovira O, Ricart W,
- 589 Fernandez-Real JM. Circulating irisin and myostatin as markers of muscle strength and physical condition in
- elderly subjects. Front Physiol. 2019;10:871
- 47. Colle SD, Morello F, Rabbia F, Milan A, Naso D, Puglisi E, Mulatero P, Veglio F. Antihypertensive drugs
- and the sympathetic nervous sysem. J Cardiovasc Pharmacol. 2007;50:487-496
- 48. Sano M. A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity. *J Cardiol*.
- 594 2018;71:471-6

644

645

# Table 1. General characteristics of study patients according to the presence of CAN

	Total	CAN (-)	CAN (+)	P-value
Frequency, n (%)	342	223 (65.2%)	119 (34.8%)	
Age (years)	56.1±11.5	55.4±11.6	57.4±11.3	0.123
Duration of diabetes	7.0±7.5	6.6±7.5	7.9±7.5	0.149
Sex (men), n (%)	199 (58.2%)	137 (61.4%)	62 (52.1%)	0.096
HbA1C (mmol/mol)	69.4±2.0	67.2±1.0	72.7±3.0	0.070
FPG (mmol/L)	8.42±2.89	8.26±2.73	8.72±3.15	0.185
Total cholesterol (mg/dL)	159±47	156±45	164±51	0.140
TG (mg/dL)	125 (90–178)	122 (90-173)	127 (91-195)	0.191
HDL-C (mg/dL)	47±11	47±11	47±11	0.778
LDL-C (mg/dL)	87±35	85±34	90±37	0.191
HTN, n (%)	119 (34.8%)	74 (33.6%)	45 (40.2%)	0.240
hsCRP (mg/L)	0.08 (0.04-0.22)	0.08 (0.04-0.23)	0.08 (0.04-0.21)	0.593
ACR	1.2 (0.6-3.7)	1.1 (0.6-3.2)	1.4 (0.6-6.2)	0.905
eGFR	90.1±17.0	90.6±17.4	87.2±20	0.096
HOMA-IR	2.9 (1.7-4.8)	2.8 (1.6-4.4)	3.2 (1.8-5.1)	0.095
BMI	25.7±4.0	25.7±3.9	25.8±4.1	0.703
HGS (kg)	29.7±9.6	30.8±9.4	27.6±9.6	0.004
Relative HGS	0.43±0.12	0.44±0.11	0.40±0.12	0.006
ASMI (kg/m²)	7.3±1.0	7.4±1.1	7.2±1.0	0.164
Low HGS, n (%)	59 (17.3%)	31 (13.9%)	28 (23.5%)	0.025
Low ASMI, n (%)	64 (18.7%)	44 (19.7%)	20 (16.8%)	0.509
Smoking, n (%)	89 (26%)	63 (28.3%)	26 (21.8%)	0.328
Alcohol, n (%)	110 (32.2%)	69 (30.9%)	41 (34.5%)	0.455
Diabetic retinopathy, n (%)	64 (25.4%)	37 (22.8%)	27 (30%)	0.211
DPN, n (%)	112 (41.8%)	66 (37.9%)	46 (48.9%)	0.081
OHA, n (%)	223 (65.2%)	149 (68%)	74 (66.1%)	0.718
Metformin, n (%)	213 (62.3%)	145 (65%)	68 (57.1%)	0.077
DPP4I, n (%)	132 (38.6%)	82 (36.8%)	50 (42%)	0.026
SGLT2I n, (%)	48 (14%)	39 (17.5%)	9 (7.6%)	0.004
GLP1RA n, (%)	17 (5%)	12 (5.4%)	5 (4.2%)	0.056
Insulin, n (%)	54 (15.8%)	34 (15.2%)	20 (16.8%)	0.051
ARB	97 (28.4%)	61 (27.4%)	36 (30.3%)	0.042
Beta blockers	16 (4.7%)	14 (6.3%)	2(1.7%)	0.011

Data are reported as mean ± standard deviation (SD) or median (interquartile range) or as number of subjects (percentage).

ACR, Albumin/creatinine ratio; ARB, angiotensin receptor blocker; ASMI, appendicular skeletal muscle index;
 BMI, body mass index; CAN, cardiovascular autonomic neuropathy; DPN, diabetic peripheral neuropathy;

50 DPP4I, dipeptidyl peptidase-4 inhibitor; FPG, fasting plasma glucose; GLP1RA, glucagon like peptide-1

651 receptor agonist; HbA1C, glycated hemoglobin; HDL-C, high density lipoprotein-cholesterol; HGS, handgrip

652 strength; HOMA-IR, homeostasis model assessment–insulin resistance; hsCRP, high-sensitivity c-reactive

protein; LDL-C, low density lipoprotein-cholesterol; OHA, oral hypoglycemic agent; SGLT2I, sodium-glucose
 cotransporter 2 inhibitor; TG, triglyceride

655

Table 2. Correlation analyses for relative HGS, ASMI, and CAN score with clinical variables in total subjects

	Relative HGS	ASMI	CAN Score
	r (p-value)	R (p-value)	R (p-value)
Relative HGS	-	0.334 (<0.001)	-0.137 (0.012)
ASMI	0.334 (<0.001)	-	-0.051 (0.350)
CAN score	-0.137 (0.012)	-0.051 (0.350)	-
Age (years)	-0.116 (0.032)	-0.403 (<0.001)	0.09 (0.097)
Duration of diabetes (years)	-0.01 (0.861)	-0.042 (0.445)	0.061 (0.263)
FPG (mg/dL)	-0.132 (0.015)	-0.021 (0.705)	0.023 (0.668)
HbA1c (%)	-0.119 (0.03)	-0.023 (0.675)	0.102 (0.064)
TC (mg/dL)	-0.06 (0.272)	-0.014 (0.790)	0.006 (0.910)
TG (mg/dL)	-0.103 (0.057)	0.192 (<0.001)	-0.033 (0.542)
HDL-C (mg/dL)	-0.026 (0.640)	-0.172 (0.002)	0.07 (0.215)
LDL-C (mg/dL)	-0.041 (0.461)	0.021 (0.707)	0.008 (0.881)
hsCRP (mg/L)	-0.201 (0.003)	0.047 (0.486)	-0.02 (0.770)
ACR	-0.108 (0.071)	0.017 (0.780)	0.03 (0.620)
eGFR	0.036 (0.513)	0.158 (0.003)	-0.089 (0.101)
BMI	-0.387 (<0.001)	0.439 (<0.001)	-0.003 (0.959)
HOMA-IR	-0.198 (0.001)	0.12 (0.049)	0.027 (0.659)

ACR, Albumin/creatinine ratio; ASMI, appendicular skeletal muscle index; BMI, body mass index; CAN,
cardiovascular autonomic neuropathy; FPG, fasting plasma glucose; HbA1C, glycated hemoglobin; HDL-C,
high density lipoprotein-cholesterol; HGS, handgrip strength; HOMA-IR, homeostasis model assessment–
insulin resistance; hsCRP, high-sensitivity c-reactive protein; LDL-C, low density lipoprotein-cholesterol; TG,
triglyceride











- ...

## 7 Table 3. Multiple logistic regression analysis of the association of sarcopenia with presence of CAN

1	Uδ

	Model 1		Model 2	
	PRs (95% CI)	P-value	PRs (95% CI)	P-value
Relative HGS				
Quartile 1	2.1 [1.1, 3.9]	0.021	4.4 [1.1, 17.3]	0.033
Quartile 2	1.3 [0.7, 2.5]	0.422	2.3 [0.8, 6.9]	0.126
Quartile 3	1.2 [0.6, 2.2]	0.622	1.2 [0.4, 3.7]	0.731
Quartile 4	1 [Reference]		1 [Reference]	
ASMI				
Quartile 1	1.2 [0.6, 2.2]	0.601	1.4 [0.3, 6.7]	0.648
Quartile 2	1.1 [0.6, 2.1]	0.75	1.2 [0.3, 5.3]	0.775
Quartile 3	1.1 [0.6, 2.0]	0.831	1.1 [0.3, 4.0]	0.835
Quartile 4	1 [Reference]		1 [Reference]	